Cyclacel Pharmaceuticals, Inc.
Cyclacel Pharmaceuticals, Inc.（CYCC）内幕交易
基于 SEC Form 4 的买入/卖出笔数、买卖比与情绪标签；可在本季度与近12个月之间切换；下方为季度图与交易明细。
SEC EDGAR · FMP · CYCC · 截至 2026年6月9日
活动摘要
买入笔数
0
P-Purchase only
卖出笔数
2
近12个月
买卖比
0.00
Buy/Sell (by trades)
整体情绪
Cyclacel Pharmaceuticals, Inc.内部人在过去近12个月主要在卖出股份，卖出行为通常由预设的Rule 10b5-1计划驱动，不一定代表对公司的负面看法。
▸ 数据来源：SEC EDGAR · Form 3 & 4 · 买入仅计P-Purchase · 卖出仅计S-Sale
截至 2026年6月9日
CYCC 季度内部人买卖趋势
CYCC 内幕交易卖出 · CYCC 内幕交易买入 · 季度活动
Mobile shows last 4Q · Desktop shows full 8Q
▸ 数据来源：SEC EDGAR · Form 3 & 4 · 最近8季度
As of Jun 9, 2026
活跃内部人
近12个月交易最活跃 · CYCC CEO内幕交易
显示全部内部人 · 点击卡片过滤下方交易表
▸ 按reportingName聚合 · 近12月交易次数Top5 · 无额外API
近期内幕交易记录
CYCC 高管卖出股份 · CYCC 董事内幕交易 · SEC Form 4申报
横向滑动查看全部列
| 日期 | 内部人 | 类型 | 股数 | 总金额 | 申报 |
|---|---|---|---|---|---|
| Sep 5, 2025 | Kua Khai Loon 10 percent owner | Sale | 19,054 | $134K | Form 4 |
| Sep 4, 2025 | Yap Kim Choy 10 percent owner | Other | 186,465 | — | Form 4 |
| Sep 4, 2025 | Kua Khai Loon 10 percent owner | Other | 186,465 | — | Form 4 |
| Sep 4, 2025 | Ong Yee Lung 10 percent owner | Other | 186,465 | — | Form 4 |
| Jul 30, 2025 | Lazar David E. 10 percent owner | Sale | 6,750 | $83K | Form 4 |
| Feb 26, 2025 | Lazar David E. Interim CEO | Option | 191,978,820 | — | Form 4 |
| Feb 26, 2025 | Lazar David E. Interim CEO | Option | 2,650,000 | — | Form 4 |
| Feb 26, 2025 | Lazar David E. Interim CEO | Sale | 194,628,820 | $5.51M⚡ | Form 4 |
| Jan 2, 2025 | NATAN DAVID Director | Award | 100,000 | — | Form 4 |
| Jan 29, 2024 | SCHWARTZ BRIAN Interim Chief Medical Officer · Director | Award | 12,500 | — | Form 4 |
| Dec 21, 2023 | McBarron Paul See Remarks · Director | Purchase | 1,886 | $6K | Form 4 |
| Dec 21, 2023 | Rombotis Spiro George President and CEO · Director | Purchase | 6,070 | $20K | Form 4 |
| Jun 30, 2023 | BARKER SAM L Director | Award | 21,219 | — | Form 4 |
| Jun 30, 2023 | Spiegel Robert J. Director | Award | 21,219 | — | Form 4 |
| Jun 30, 2023 | Walker Karin L Director | Award | 21,219 | — | Form 4 |
| Jun 30, 2023 | Ferguson Kenneth M. Director | Award | 21,219 | — | Form 4 |
| Jun 30, 2023 | HENNEY CHRISTOPHER S Director | Award | 21,219 | — | Form 4 |
| Jun 30, 2023 | SCHWARTZ BRIAN Director | Award | 21,219 | — | Form 4 |
| Jan 31, 2023 | McBarron Paul See Remarks · Director | Award | 31,200 | — | Form 4 |
| Jan 31, 2023 | Rombotis Spiro George President and CEO · Director | Award | 57,600 | — | Form 4 |
| Jan 31, 2023 | Kirschbaum Mark Chief Medical Officer | Award | 31,200 | — | Form 4 |
| Jun 14, 2022 | Ferguson Kenneth M. Director | Award | 27,733 | — | Form 4 |
| Jun 14, 2022 | Sems Lloyd Director | Award | 15,822 | — | Form 4 |
| Jun 14, 2022 | SCHWARTZ BRIAN Director | Award | 15,822 | — | Form 4 |
| Jun 14, 2022 | HENNEY CHRISTOPHER S Director | Award | 15,822 | — | Form 4 |
SCHWARTZ BRIAN
Interim Chief Medical Officer · Director
日期
Jan 29
股数
12,500
均价
—
总金额
—
Rombotis Spiro George
President and CEO · Director
日期
Dec 21
股数
6,070
均价
$3.31
总金额
$20K
⚡ = 金额≥$100万 · Award/Option价格显示— · 仅Form4 · 仅普通股
▸ 数据来源：SEC EDGAR · Form 4 申报 · ⚡ = 金额≥$100万 · Award/Option 价格显示 —
关于 CYCC 内幕交易
CYCC 内幕交易
Cyclacel Pharmaceuticals, Inc.（CYCC）内幕交易数据来源于公司内部人（包括Kua Khai Loon (10 percent owner), Yap Kim Choy (10 percent owner), Ong Yee Lung (10 percent owner)）提交的SEC Form 4申报文件。过去12个月内，4位内部人向SEC提交了交易申报。CYCC内部人近期主要在卖出，这可能反映预设的10b5-1计划执行，而非方向性判断。
如需查看Cyclacel Pharmaceuticals, Inc.机构持仓比例和内部人持股百分比，请访问持仓（Ownership）标签页 → Ownership tab →
常见问题
CYCC 内幕交易 · 5个问题Cyclacel Pharmaceuticals, Inc.（CYCC）的内部人包括高管和董事，如Kua Khai Loon (10 percent owner), Yap Kim Choy (10 percent owner), Ong Yee Lung (10 percent owner)等。过去12个月内，4位内部人向SEC提交了Form 4交易申报。内部人须在交易日期后2个工作日内完成申报。
▸ 数据来源：FMP /stable/insider-trading/search · SEC EDGAR Form 3 & 4 · RSU归属不计入情绪 · As of Jun 9, 2026